WATERTOWN, Mass. , Nov. 11, 2021 /PRNewswire/ --  Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

- LYR-210 Phase 3 ENLIGHTEN and LYR-220 Phase 2 BEACON studies on track to initiate around EOY - - New LYR-210 Phase 2 LANTERN 6-month follow up data and LYR-210 PK study presented at ARS Annual Meeting - - Jason Cavalier appointed as Chief Financial Officer - WATERTOWN, Mass. , Nov.

WATERTOWN, Mass. , Nov. 2, 2021 /PRNewswire/ -- Lyra Therapeutics , Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

WATERTOWN, Mass. , Oct. 19, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA ), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

Approximately 50% of treated CRS patients experienced durable symptom improvement six months after treatment with LYR-210 (7500μg) LYR-210 pharmacokinetics indicate a constant and steady daily dose of Mometasone Furoate is delivered to patients LANTERN study manuscript wins ARS Annual Meeting 2021

LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis Patients Company to Initiate Phase 3 ENLIGHTEN Program around YE’21 WATERTOWN, Mass., Sept.

LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of

Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role WATERTOWN, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,

Results demonstrate XTreo ™ technology platform provides targeted and sustained dosing of anti-inflammatory medication Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3

WATERTOWN, Mass. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other